Table 3.
Adipose tissue myeloid cell populations
| Castrate (n = 7) |
Low T/E (n = 9) |
Normal T/E (n = 9) |
Normal T/Low E (n = 12) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 4 | Baseline | Week 4 | Baseline | Week 4 | Baseline | Week 4 | P Value (Overall RM-ANOVA) | |
| ATMs | |||||||||
| CD14+206+, cells/g AT | 30 (18) | 54 (31) | 47 (27) | 56 (49) | 47 (37) | 36 (21) | 54 (41) | 66 (63) | 0.65 |
| CD14+206+, %CD45+ cells | 1.9 (1.1) | 2.4 (1.8) | 3.8 (2.3) | 3.9 (4.0) | 3.0 (1.7) | 2.3 (2.2) | 3.4 (2.1) | 3.1 (1.4) | 0.57 |
| ATM subsets | |||||||||
| CD11c+, cells/g AT | 7 (5) | 15 (10) | 10 (11) | 15 (18) | 12 (13) | 10 (7) | 10 (7) | 15 (26) | 0.59 |
| CD11c+, %ATMs | 22.3 (12.3) | 28.7 (11.5) | 21.8 (19.7) | 25.9 (23.9) | 28.6 (18.9) | 29.6 (17.4) | 21.8 (16.6) | 21.4 (17.7) | 0.67 |
| ABCA1+, cells/g AT | 8 (16) | 16 (25) | 11 (17) | 12 (26) | 8 (14) | 5 (9) | 3 (7) | 12 (25) | 0.73 |
| ABCA1+, %ATMs | 16.6 (31.6) | 25.2 (38.0) | 24.9 (41.1) | 32.5 (45.4) | 20.2 (33.1) | 14.7 (28.9) | 9.3 (21.8) | 24.8 (41.2) | 0.89 |
| CD36+, cells/g AT | 11 (9) | 15 (9) | 22 (13) | 15 (13) | 21 (32) | 13 (11) | 17 (15) | 19 (15) | 0.34 |
| CD36+, %ATMs | 37.0 (15.4) | 33.0 (19.8) | 50.0 (23.9) | 30.1 (17.6) | 41.9 (28.2) | 33.7 (22.0) | 33.7 (22.4) | 32.9 (19.7) | 0.25 |
| CD40+, cells/g AT | 1 (0.7) | 2 (1) | 2 (1) | 2 (1) | 2 (2) | 3 (5) | 2 (1) | 3 (2) | 0.18 |
| CD40+, %ATMs | 3.4 (1.6) | 4.0 (0.8) | 3.7 (1.1) | 2.8 (1.9) | 3.7 (1.4) | 5.6 (5.1) | 2.9 (1.2) | 4.4 (3.9) | 0.03* |
| CD163+, cells/g AT | 9 (6) | 21 (20) | 15 (11) | 34 (44) | 16 (17) | 13 (10) | 24 (24) | 23 (20) | 0.54 |
| CD163+, %ATMs | 48.7 (36.6) | 48.7 (34.1) | 40.1 (31.3) | 45.7 (35.0) | 39.9 (35.7) | 41.8 (31.5) | 44.2 (36.2) | 45.2 (33.4) | 0.45 |
| Neutrophils | |||||||||
| CD15+16+, cells/g AT | 740 (208) | 1,350 (1,150) | 688 (467) | 1,000 (730) | 1,000 (588) | 1,500 (1,470) | 791 (637) | 887 (782) | 0.84 |
| CD15+16+, %CD45+ cells | 52.4 (7.8) | 50.1 (18.4) | 46.7 (12.0) | 47.7 (19.3) | 57.1 (9.9) | 54.0 (22.5) | 38.4 (16.3) | 35.4 (21.7) | 0.97 |
| NK cells | |||||||||
| CD16+, cells/g AT | 38 (19) | 40 (20) | 34 (23) | 41 (15) | 28 (13) | 34 (21) | 36 (21) | 42 (21) | 0.93 |
| CD16+, %CD45+ cells | 2.7 (1.0) | 1.7 (0.5) | 2.3 (1.2) | 2.2 (1.6) | 1.8 (0.8) | 2.1 (1.8) | 2.3 (1.2) | 2.6 (1.9) | 0.61 |
| Dendritic cells | |||||||||
| CD1c+, cells/g AT | 13 (9) | 36 (22) | 11 (12) | 15 (10) | 9 (7) | 15 (10) | 10 (7) | 27 (27) | 0.87 |
| CD1c+, %CD45+ cells | 1.0 (0.6) | 1.6 (1.4) | 0.7 (0.7) | 0.9 (0.8) | 0.6 (0.7) | 0.8 (0.7) | 0.8 (0.6) | 1.4 (0.9) | 0.57 |
Data are shown as means (SD), and cell numbers are shown in thousands. Baseline and end-of-treatment myeloid cell populations in adipose tissue (AT). ATMs, adipose tissue macrophages. P values represent time-by-group interactions from RM-ANOVA comparing all treatment arms at baseline and week 4.
*
denotes statistical significance.